Higher variability in the NSCLC model may reflect greater genetic heterogeneity and fundamental differences in pancreatic versus lung tumor development when transformed by mutant Kras (Chung et al., in prep). This evidence concerns the gene KRAS and non-small cell lung carcinoma.